Cambridge Investment Research Advisors’s NeuroOne Medical Technologies NMTC Stock Holding History

Cambridge Investment Research Advisors’s Portfolio NMTC Stock Details NMTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$87K	Sell	28,499 -1	-0%	-$4	﹤0.01%	3943
2026 Q1	$133K	Hold	28,500	–	–	﹤0.01%	3752
2025 Q4	$130K	Buy	28,500 +8,333	+41%	+$38K	﹤0.01%	3664
2025 Q3	$108K	Buy	20,167 +6,667	+49%	+$32.6K	﹤0.01%	3584
2025 Q2	$55K	Hold	13,500	–	–	﹤0.01%	3533
2025 Q1	$69K	Buy	+13,500	New	+$85.7K	﹤0.01%	3385
2024 Q3	–	Sell	-1,733	Closed	-$8K	–	3493
2024 Q2	$8K	Buy	+1,733	New	+$10.9K	﹤0.01%	3298

Other funds holding NMTC

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Bard Associates Chicago, Illinois $451M AUM 66.6% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

EIM

Essex Investment Management Boston, Massachusetts $763M AUM 108.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Cambridge Investment Research Advisors's NMTC Position: Q2 2026 in Review

Cambridge Investment Research Advisors reduced its NeuroOne Medical Technologies (NMTC) stake by 0% in Q2 2026, selling an estimated $4 and leaving 28,499 shares worth $87K. The position accounts for ﹤0.01% of the portfolio, ranked #3943.

Cambridge Investment Research Advisors first reported a position in NMTC in Q2 2024 and has held it in 7 quarters since. The position peaked at $133K in Q1 2026. 26 funds tracked by Wall St. Rank hold NMTC as of Q2 2026.

Cambridge Investment Research Advisors held 28,499 shares of NeuroOne Medical Technologies worth $87K as of Q2 2026.
Cambridge Investment Research Advisors sold 1 NeuroOne Medical Technologies share in Q2 2026, an estimated $4.
NeuroOne Medical Technologies made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #3943 holding.
Cambridge Investment Research Advisors first reported a position in NeuroOne Medical Technologies in Q2 2024 and has held it in 7 quarters since.
Cambridge Investment Research Advisors's NeuroOne Medical Technologies position peaked at $133K in Q1 2026.
26 funds tracked by Wall St. Rank held NeuroOne Medical Technologies as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.